Press Releases and News 

Pluristyx and Accelerated Biosciences announce availability of clinical-grade immune-privileged human trophoblast stem cells (hTSCs)

Pluristyx and Accelerated Biosciences announce availability of clinical-grade immune-privileged human trophoblast stem cells (hTSCs)

April 27, 2022

Pluristyx announces strategic alliance with panCELLa and Implant Therapeutics of offer 'off-the-shelf' induced pluripotent stem cells.

Pluristyx announces strategic alliance with panCELLa and Implant Therapeutics of offer 'off-the-shelf' induced pluripotent stem cells.

January 20, 2022

Accelerated Biosciences’ Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and Regenerative Medicine Treatments

Accelerated Biosciences’ Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and Regenerative Medicine Treatments

May 11, 2021

AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications

AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications

June 16, 2020

Pluristyx to Support Development of Kiadis’ K-NK Cell COVID-19 Therapy Funded by $9.5 Million From the Advanced Regenerative Manufacturing Institute’s BioFabUSA Program

Pluristyx to Support Development of Kiadis’ K-NK Cell COVID-19 Therapy Funded by $9.5 Million From the Advanced Regenerative Manufacturing Institute’s BioFabUSA Program

November 12, 2020